Rethinking Go-to-Market Strategy with Innovation in a Patient-Centric Era

EP: 1.Current Perspective on Pricing and Reimbursement Models

EP: 2.Overcoming Regulatory Barriers to Market Access

EP: 3.Delivering Value Beyond the Trial with Real-World Evidence

EP: 4.Aligning Real-World Evidence with Payer Perspectives

EP: 5.Navigating Market Entry Challenges for Orphan Drugs

EP: 6.Effective Tactics for Pricing and Reimbursement in Today’s Market

EP: 7.Designing Effective Value-Based Contracts: Timing, Evidence, and Risk Alignment

EP: 8.Planning for Market Sustainability Under New Policy Frameworks

Now Viewing

EP: 9.Rethinking Go-to-Market Strategy with Innovation in a Patient-Centric Era

As the series closes, the panel reflects on an often underrepresented but crucial stakeholder: the patient. The discussion underscores the need for a more patient-centered market access strategy—one that incorporates health equity, diagnostic and treatment journey support, and clearer communication around cost and adherence.

Key discussion topics include:

• How social determinants of health (SDOH) shape real-world treatment access.
• The growing need for payer transparency and patient trust in the marketplace.
• Strategies to engage patients early in development to ensure success.